Edlund, P. (2011) “Dose-tailoring of FEC adjuvant chemotherapy based on leukopenia is feasible and well tolerated. Toxicity and dose intensity in the Scandinavian Breast Group phase 3 adjuvant Trial SBG 2000-1”, Acta Oncologica, 50(3), pp. 329–337. doi: 10.3109/0284186X.2011.554435.